Billions of dollars are spent every year to help patients with type 2 diabetes manage their insulin and control their blood sugar, but Fractyl Laboratories Inc. is trying to address the root cause of insulin resistance with its Revita duodenal mucosal resurfacing (DMR) system.
"It's just not enough to think about [type 2 diabetes] as a blood-sugar disease that needs to be managed with insulin or glucose monitoring," Fractyl CEO Harith Rajagopalan told Medtech...
Type 2 diabetes is a major risk factor for cardiovascular, liver and kidney disease and afflicts 400 million people worldwide, including 30 million in the US. About 5 million people...